scholarly journals Diagnostic value of breast ultrasound in mammography BI-RADS 0 and clinically indeterminate or suspicious of malignancy breast lesions

2016 ◽  
Vol 73 (3) ◽  
pp. 239-245 ◽  
Author(s):  
Aleksandar Dobrosavljevic ◽  
Snezana Rakic ◽  
Branka Nikolic ◽  
Svetlana Jankovic-Raznatovic ◽  
Svetlana Dragojevic-Dikic ◽  
...  
Keyword(s):  
Breast Imaging ◽  
Breast Tissue ◽  
Diagnostic Value ◽  
Surgical Biopsy ◽  
Breast Masses ◽  
Intramammary Lymph Node ◽  
The Difference ◽  
Palpable Breast

Background/Aim. Not only that ultrasound makes the difference between cystic and solid changes in breast tissue, as it was the case at the beginning of its use, but it also makes the differential diagnosis in terms of benign-malignant. The aim of this study was to assess the role of sonography in the diagnosis of palpable breast masses according to the American College of Radiology Ultrasonographic Breast Imaging Reporting and Data System (BI-RADS) and to correlate the BI-RADS 4 and BI-RADS 5 category with pathohistological findings. Methods. A retrospective study was conducted with the breast sonograms of 30 women presented with palpable breast masses found to be mammography category BI-RADS 0 and ultrasonographic BI-RADS categories 4 and 5. The sonographic categories were correlated with pathohistological findings. Results. Surgical biopsy in 30 masses revealed: malignancy (56.7%), fibroadenoma (26.7%), fibrocystic dysplasia with/without atypia (10%), lipoma (3.3%) and intramammary lymph node (3.3%). Correlation between BI-RADS categories and pathohistological findings was found (p < 0.05). All BI-RADS 5 masses were malignant, while in BI-RADS 4A category fibroadenomas dominated. A total of 53.8% of all benign lesions were found in women 49 years of age or younger as compared with 35.3% of all malignancies in this group (p < 0.05). Conclusion. Ultrasonography BI-RADS improved classification of breast masses. The ultrasound BI-RADS 4 (A, B, C) and BI-RADS 5 lesions should be worked-up with biopsy.

scholarly journals Mushroom Biomass: Some Clinical Implications of β-Glucans and Enzymes

2016 ◽  
Vol 4 (Special-Issue-October) ◽  
pp. 37-47
Author(s):  
Ana Barros ◽  
Vitoria Bell ◽  
Jorge Ferrão ◽  
Vittorio Calabrese ◽  
Tito Fernandes
Keyword(s):  
Secondary Metabolites ◽  
Dietary Supplement ◽  
Biological Response ◽  
Cellular Growth ◽  
Health Promoting ◽  
The Rich ◽  
The Difference ◽  
Cytochrome P 450

Mushrooms have attracted market attention because they are a potential source of bioactive compounds able to perform several functions in organisms with benefits for the health of the consumer. Cultivation processes vary according a) industrial fermentation - in large vats to produce extracted form of mushrooms or b) closed cultivation system - individually grown in jars on an aseptic “substrate” with controlled lighting and irrigation to produce a biomass form of mushrooms. Biomass is the mycelium with primordia (young fruiting body - before the mushroom blooms) containing all the nutrients and active compounds, including β-glucans, enzymes and secondary metabolites. The classification of mushroom biomass varies according to the presentation; the biomass can be classified as a “food” if in powder form or, classified as a “dietary supplement” in tablet form. While tablet mushroom biomass is considered a dietary supplement, mushroom extracts are designated pharmaceutical compounds, pharmanutrients or nutraceuticals. Here we illustrate the difference between mushrooms in the biomass and extract forms, the similarities and differences on its content on enzymes, secondary metabolites and on β-glucans, as a soluble and fermentable fibre. Of particular note is the rich enzyme activity in the biomass form of mushrooms. Such activity includes enzymes that prevent oxidative stress (superoxide dismutase), enzymes that prevent cellular growth (protease, glucoamylase) and enzymes that promote detoxification (cytochrome P-450, peroxidase, glucose-2-oxidase). β-glucans have been proposed to act as “biological response modifiers” based on their effects on the immune system, and its role in the prevention and treatment of various metabolic syndrome-linked diseases. This review focuses also on some described health-promoting potential of mushroom biomass, all through immunomodulation. The role of intestinal microbiota is enhanced.

Role of contrast-enhanced spectral mammography in the post biopsy management of B3 lesions: Preliminary results

2018 ◽  
Vol 105 (5) ◽  
pp. 378-387 ◽  
Author(s):  
Giulia Bicchierai ◽  
Jacopo Nori ◽  
Diego De Benedetto ◽  
Cecilia Boeri ◽  
Ermanno Vanzi ◽  
...  
Keyword(s):  
Breast Imaging ◽  
Surgical Excision ◽  
Surgical Biopsy ◽  
Predictive Values ◽  
Contrast Enhanced ◽  
B3 Lesions ◽  
Malignant Lesions ◽  
Sensitivity Specificity

PurposeTo evaluate the role of contrast-enhanced spectral mammography (CESM) in the post biopsy management of breast lesions classified as lesions of uncertain malignant potential (B3) by core needle biopsy and vacuum-assisted biopsy (VAB).MethodsThe local ethics committee approved this retrospective study and for this type of study formal consent is not required. A total of 42 B3 lesions in 40 women aged 41–77 years were included in our study. All patients underwent CESM 2–3 weeks after the biopsy procedure and surgical excision was subsequently performed within 60 days of the CESM procedure. Three radiologists reviewed the images independently. The results were then compared with histologic findings.ResultsThe sensitivity, specificity, and positive and negative predictive values for confirmed demonstration of malignancy at CESM were 33.3%, 87.2%, 16.7%, and 94.4% for reader 1; 66.7%, 76.9%, 18.2%, and 96.7% for reader 2; 66.7%, 74.4%, 16.7%, and 96.7% for reader 3. Overall agreement on detection of malignant lesions using CESM among readers ranged from moderate to substantial (κ = .451–.696), for categorization of BPE from moderate to substantial (κ = .562–.711), and for evaluation of lesion intensity enhancement from fair to moderate (κ = .346–.459).ConclusionIn cases of Breast Imaging Reporting and Data System (BI-RADS) 1, BI-RADS 2, or BI-RADS 3 results at CESM, follow-up or VAB rather than surgical biopsy might be performed.

scholarly journals A New Computer-Aided Diagnosis System with Modified Genetic Feature Selection for BI-RADS Classification of Breast Masses in Mammograms

2020 ◽  
Vol 2020 ◽  
pp. 1-17 ◽  
Author(s):  
Said Boumaraf ◽  
Xiabi Liu ◽  
Chokri Ferkous ◽  
Xiaohong Ma
Keyword(s):  
Feature Selection ◽  
Predictive Value ◽  
Breast Imaging ◽  
Feature Selection Method ◽  
Computer Aided Diagnosis ◽  
Screening Mammography ◽  
Breast Masses ◽  
Computer Aided ◽  
Aided Diagnosis

Mammography remains the most prevalent imaging tool for early breast cancer screening. The language used to describe abnormalities in mammographic reports is based on the Breast Imaging Reporting and Data System (BI-RADS). Assigning a correct BI-RADS category to each examined mammogram is a strenuous and challenging task for even experts. This paper proposes a new and effective computer-aided diagnosis (CAD) system to classify mammographic masses into four assessment categories in BI-RADS. The mass regions are first enhanced by means of histogram equalization and then semiautomatically segmented based on the region growing technique. A total of 130 handcrafted BI-RADS features are then extracted from the shape, margin, and density of each mass, together with the mass size and the patient’s age, as mentioned in BI-RADS mammography. Then, a modified feature selection method based on the genetic algorithm (GA) is proposed to select the most clinically significant BI-RADS features. Finally, a back-propagation neural network (BPN) is employed for classification, and its accuracy is used as the fitness in GA. A set of 500 mammogram images from the digital database for screening mammography (DDSM) is used for evaluation. Our system achieves classification accuracy, positive predictive value, negative predictive value, and Matthews correlation coefficient of 84.5%, 84.4%, 94.8%, and 79.3%, respectively. To our best knowledge, this is the best current result for BI-RADS classification of breast masses in mammography, which makes the proposed system promising to support radiologists for deciding proper patient management based on the automatically assigned BI-RADS categories.

Sonoelastography for 1786 non-palpable breast masses: diagnostic value in the decision to biopsy

2011 ◽  
Vol 22 (5) ◽  
pp. 1033-1040 ◽  
Author(s):  
Ann Yi ◽  
Nariya Cho ◽  
Jung Min Chang ◽  
Hye Ryoung Koo ◽  
Bo La Yun ◽  
...  
Keyword(s):  
Diagnostic Value ◽  
Breast Masses ◽  
Palpable Breast

The role of pentraxin 3 as diagnostic value in classification of patients with heart failure

2013 ◽  
Vol 46 (12) ◽  
pp. 983-987 ◽  
Author(s):  
Sermin Duran ◽  
Ilyas Duran ◽  
Fatma Asuman Orçun Kaptanagası ◽  
Filiz Nartop ◽  
Hilmi Ciftci ◽  
...  
Keyword(s):  
Heart Failure ◽  
Diagnostic Value ◽  
Pentraxin 3 ◽  
Patients With Heart Failure

Role of contrast enhanced mammography in diagnosis of malignant breast lesion with histopathological correlation

QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Shaimaa Khalil Abd El-Maged Mohamed ◽  
Naglaa Hussien Shebreya ◽  
Manal Mohamed El-mahdy ◽  
Amal Amin Abo Elmaati ◽  
Merehan Ahmed Nasr
Keyword(s):  
Predictive Value ◽  
Breast Imaging ◽  
Breast Tissue ◽  
False Negative ◽  
Radiology Department ◽  
Breast Clinic ◽  
Intravenous Contrast ◽  
Cross Sectional ◽  
Contrast Enhanced

Abstract Background Contrast-enhanced spectral mammography (CESM) is a relatively new tool in breast imaging, which combines the benefits of full field digital mammography (FFDM) with intravenous contrast utilization. FFDM alone is a two-dimensional modality in which summation of overlapping tissues accounts for false-negative and false-positive findings, resulting in increased recall rates and limited sensitivity of the examination, especially in the setting of heterogeneously dense or extremely dense breast tissue. CESM advantageously uses the concept of angiogenesis in tumors by allowing contrast agents to highlight the areas of blood vessel proliferation relative to the surrounding normal breast tissue (Bhimani et al, 2017). Objectives The purpose of this study is to assess the role of contrast-enhanced (CEM) mammography for detecting malignant lesions compared to histopathological results. Methods A cross sectional study including 35 patients suspecting breast mass clinically, concluded at Ain Shams University hospitals, Radiology Department, in the outpatient breast clinic, the patients were investigated using SenoBright spectral mammography device, the period between January 2018 till the end of b June 2019. Results In our study CESM had a sensitivity of 95.7 %, a specificity of 66.7 %, a positive predictive value of 84.6% (PPV), a negative predictive value of 88.9 % (NPV) and efficacy 85.7 %. Conclusions CESM has better diagnostic performance than the standard conventional imaging; mammography plus ultrasound and provides a valuable tool to evaluate equivocal and suspicious breast lesions and detect multifocal/multicenteric disease accurately.

scholarly journals The role of Tru-cut needle biopsy in the diagnosis of palpable breast masses.

2014 ◽  
Vol 56 (3) ◽  
pp. 292-295
Author(s):  
Mahmood H. Hassan ◽  
◽  
Ahmed R. Hizam ◽  
Safa M. Al-Obaidi ◽  
◽  
...  
Keyword(s):  
Needle Biopsy ◽  
Breast Masses ◽  
Palpable Breast
Sign in / Sign up

Export Citation Format

Share Document